Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ogd2 Pharma is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, DENT, ALANA HARRIS. As the busiest examiner for the company, DENT, ALANA HARRIS holds the 1 busiest examiner pending office action. This represents a very focused and singular prosecution effort.
The entire pending portfolio is located within 1 distinct art unit. For a practitioner, this means that the outcome of the company's current patent efforts is entirely dependent on the decisions made within this 1 distinct art unit and by this 1 distinct examiner. There is no diversity in the prosecution profile to mitigate the risk of a single examiner's perspective. With only 1 pending office action, the current workload is light, but the concentration of that workload means that every interaction with DENT, ALANA HARRIS is critical for the company's intellectual property goals.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18555459 | NEW METHOD TO IMPROVE NK CELLS CYTOTOXICITY | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18555459 | NEW METHOD TO IMPROVE NK CELLS CYTOTOXICITY | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | — | Pending | Oct 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOgd2 Pharma has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alana Harris Dent has the most, with 1 of Ogd2 Pharma's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
